You just read:

AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint

News provided by

AbbVie

Dec 12, 2017, 06:30 EST